The Food and Drug Administration said earlier this month that it was accepting public comments on CBD regulations.
Already over 400 people have shared their comments with the agency which have been published on Regulations.gov.
The comments range widely in subject matter, but many have commented that marijuana in general should be legalized.
The ironic part is that the agency did not request comments in on this particular issue.
There will be an upcoming public hearing on CBD regulations that the FDA is holding on May 31st.
Dr. Amy Abernethy, the principal Deputy Commissioner and Acting CIO at @US_FDA, tweeted, “Are there particular safety concerns re: products with cannabis/cannabis-derived compounds? How does the mode of delivery (e.g., ingestion, absorption, inhalation) affect the safety & exposure? Comments/data on important issues like these can help inform FDA reg. oversight.